Your browser doesn't support javascript.
loading
Production of monoclonal antibodies against botulinum neurotoxin in Nicotiana benthamiana.
Sangprasat, Kornchanok; Bulaon, Christine Joy I; Rattanapisit, Kaewta; Srisangsung, Theerakarn; Jirarojwattana, Perawat; Wongwatanasin, Apidsada; Phoolcharoen, Waranyoo.
Afiliación
  • Sangprasat K; Center of Excellence in Plant-Produced Pharmaceuticals, Chulalongkorn University, Bangkok, Thailand.
  • Bulaon CJI; Department of Pharmacognosy and Pharmaceutical Botany, Faculty of Pharmaceutical Sciences, Chulalongkorn University, Bangkok, Thailand.
  • Rattanapisit K; Graduate Program of Program in Research for Enterprise, Chulalongkorn University, Bangkok, Thailand.
  • Srisangsung T; Department of Research and Development, Baiya Phytopharm Co. Ltd, Bangkok, Thailand.
  • Jirarojwattana P; Department of Research and Development, Baiya Phytopharm Co. Ltd, Bangkok, Thailand.
  • Wongwatanasin A; Center of Excellence in Plant-Produced Pharmaceuticals, Chulalongkorn University, Bangkok, Thailand.
  • Phoolcharoen W; Department of Pharmacognosy and Pharmaceutical Botany, Faculty of Pharmaceutical Sciences, Chulalongkorn University, Bangkok, Thailand.
Hum Vaccin Immunother ; 20(1): 2329446, 2024 Dec 31.
Article en En | MEDLINE | ID: mdl-38525945
ABSTRACT
Botulism is a fatal neurologic disease caused by the botulinum toxin (BoNT) produced by Clostridium botulinum. It is a rare but highly toxic disease with symptoms, such as cramps, nausea, vomiting, diarrhea, dysphagia, respiratory failure, muscle weakness, and even death. Currently, two types of antitoxin are used equine-derived heptavalent antitoxin and human-derived immunoglobulin (BabyBIG®). However, heptavalent treatment may result in hypersensitivity, whereas BabyBIG®, has a low yield. The present study focused on the development of three anti-BoNT monoclonal antibodies (mAbs), 1B18, C25, and M2, in Nicotiana benthamiana. The plant-expressed mAbs were purified and examined for size, purity and integrity by SDS-PAGE, western blotting and size-exclusion chromatography. Analysis showed that plant-produced anti-BoNT mAbs can fully assemble in plants, can be purified in a single purification step, and mostly remain as monomeric proteins. The efficiency of anti-BoNT mAbs binding to BoNT/A and B was then tested. Plant-produced 1B18 retained its ability to recognize both mBoNT/A1 and ciBoNT/B1. At the same time, the binding specificities of two other mAbs were determined C25 for mBoNT/A1 and M2 for ciBoNT/B1. In conclusion, our results confirm the use of plants as an alternative platform for the production of anti-BoNT mAbs. This plant-based technology will serve as a versatile system for the development botulism immunotherapeutics.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Botulismo / Antitoxinas / Toxinas Botulínicas Tipo A Límite: Animals / Humans Idioma: En Revista: Hum Vaccin Immunother Año: 2024 Tipo del documento: Article País de afiliación: Tailandia Pais de publicación: Estados Unidos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Botulismo / Antitoxinas / Toxinas Botulínicas Tipo A Límite: Animals / Humans Idioma: En Revista: Hum Vaccin Immunother Año: 2024 Tipo del documento: Article País de afiliación: Tailandia Pais de publicación: Estados Unidos